Evonik has been leading the market for enteric release for more than six decades thanks to a continuous pursuit for innovative coating solutions and value-adding services. Whether you are seeking to protect acid-sensitive drugs from gastric fluid, safeguard the gastric mucosa against aggressive APIs, or ensure rapid dissolution at a specific gastrointestinal site - we have the oral excipients, processing capabilities and technical expertise to address your specific enteric release requirements. They also have excellent gastro-resistant properties to avoid the degradation of acid-sensitive APIs such as enzymes, peptides or protein pump inhibitors in the stomach. All common pharmaceutical processing technologies can be utilized based upon the specific polymer grade, including aqueous and organic film coating, hot melt extrusion, spray drying, direct compression and granulation. Processing can be done at low to moderate product temperatures to help reduce energy consumption and minimize thermic stress for the API.

Author:Voodoosho Kekazahn
Language:English (Spanish)
Published (Last):2 February 2007
PDF File Size:14.61 Mb
ePub File Size:20.73 Mb
Price:Free* [*Free Regsitration Required]

Evonik, a global leader for functional excipients used in oral solid dosage forms, today announced the launch of an advanced combination polymer for enteric coatings. It can be sprayed with a smooth, fast and no-stick process for excellent adhesion. It has also been shown to reduce coating film thicknesses, creating opportunities for increased drug loading. Requests for individual meetings or product samples can be made via healthcare evonik.

About Evonik Evonik is one of the world leaders in specialty chemicals. They are the lever for profitable growth and a sustained increase in the value of the company.

Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over countries around the world with more than 36, employees. That includes applications for everyday consumer goods as well as animal nutrition and health care. Disclaimer In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties.

Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

Search on our website.


EUDRAGIT®: The success story continues

With a proven record for safe applications that spans more than 60 years backed by monographs across all major pharmacopoeias, they are ideal for use with all oral solid dosage forms including multiparticulates, regular or matrix tablets and hard or soft-gel capsules. Furthermore, all of our polymers are manufactured to a consistent high-quality, with established, audited sites helping to provide global supply security. In addition to being insoluble in saliva and readily soluble in the stomach for fast drug absorption, they feature a low viscosity, have a high pigment binding capacity and provide excellent film adhesion. Pigments can also be consistently color-matched for batch-to-batch conformity. Thus, it is the new polymer of choice for enteric coatings on multiparticulates for further compression to multi-unit tablets. Evonik has been leveraging its highly flexible portfolio for sustained release to help pharmaceutical companies optimize drug effectiveness and improve patient compliance for more than 50 years.


Highly flexible. Easy-to-Process.

For more than half a century, Evonik has been helping pharmaceutical companies to optimize oral solid dosage forms that are targeted for immediate drug release. To improve rates of brand preference and patient compliance amongst patient populations including children and the elderly, we have established a core competency in the development of dosage forms that are pleasant to feel, smell and taste, and easy to swallow. We have also gained a strong reputation in helping pharmaceutical companies protect APIs that are sensitive to light, moisture or oxygen to improve drug stability. And to save pharmaceutical companies time and cost, we developed ready-to-use powder blends.


The global market leader for enteric release coatings

As medicines continue to become more complex and personalized, pharmaceutical companies are increasingly partnering with oral excipient specialists who can enable, enhance and differentiate their oral solid dosage forms. For more than 60 years, Evonik has been leveraging its market-leading expertise in oral excipients and related drug delivery technologies to help customers generate specific functionality outcomes for their small molecules and biologics. In addition to applying our polymers, process technology and formulation expertise to match virtually any target release profile or address poor API solubility, we have a strong track record for global supply security and local regulatory support. In addition to being well-defined synthetic polymers with narrow specifications, they are neither absorbable nor biodegradable, do not change in chemical structure while passing through the body and exhibit no toxicological effects. Evonik has been a global leader in complex oral solid dosage forms for more than six decades, including capsules filled with pellets, mini-tablets, solid dispersions or liquids, multi-particulate and matrix tablets, 2D films and 3D printed multi-compartment tablets. We have the expertise and capabilities to rapidly optimize the development process and provide clinical batches for use across a range of areas including the development of orphan drugs, poorly soluble drugs, oncological drugs and pediatric formulations.

Related Articles